Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CMXC float has to be getting extremely tight! This will be 2.00 pps by end of the week!
Another new intraday 52 week high!
1.53
Up another 25% on the day as of right now.
THis stock will go into multiple dollars and uplist....once their tech is approved and licensed for sale in the US..
Already has CSA/UL approval.
Already there in Canada!
THis stock is very strong....back nipping at the high of the day in the closing minutes of the market...
Once they get approval to launch their device in the USA this stock will be airborne.
News: $CMXC Cell MedX Corp. Provides Corporate Update
Carson City, Nevada--(Newsfile Corp. - September 12, 2019) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is excited ...
Got this from CMXC - Cell MedX Corp. Provides Corporate Update
There is absolutely nothing out of the ordinary in their most recent 10K
Standard operating procedure for new companies...
And right now there are next to no shares in the float....
So diluting to raise money at this point is a non starter.
closed at 1.18 up .36
up 43.03%...on the day
THis was .42 cents on August 23rd.
Great tech...huge potential to help millions...
THis stock is under the radar and way undervalued....imo
Moved from .82 yesterday and hit a high of 1.45 before settling at 1.18
Poised to keep running...
Low float of less than 50 million....
Liquidity not an issue so far....
Moves very hard because of small float...
Like I said...when it moves..it moves hard...hit 1.45 today.....still settles up .36 on the day....
THis may go into multiple dollars before all is said and done...and uplist...a great company and hugely under the radar.
UP 43.03% on the day....
I originally found this August 23rd at .42 cents after reading a news release about their tech....since then the pr came out about their trial on real patients in BC. Canada
News: $CMXC Cell Medx Corp (OTCMKTS: CMXC) Short Squeeze
Over the past twenty days of trading, August 8th, 2019 to September 5th, 2019 there is a potential Short Squeeze about to happen because of an incr...
Read the whole news CMXC - Cell Medx Corp (OTCMKTS: CMXC) Short Squeeze
9/6/2019 10-K , not great news IMHO
https://www.sec.gov/Archives/edgar/data/1493712/000139390519000266/0001393905-19-000266-index.htm
It was because it was pumped...they did have a pr...about further testing of their device...is was promoted..and peeps got in..and then out...still a great company with huge potential if they validate their medical tech...they are carrying out testing on real patients in British Columbia Canada very soon..that was just approved...
Also very low float so when it moves it moves hard.
Less than 50 milly OS.
Wow stock went parabolic yesterday the 26th of August. Went from trading by appointment to 644,000 in volume. Interesting.
Name Age Since Current Position
Frank McEnulty
59 2017 President, Director
Yanika Silina
37 2016 Chief Financial Officer, Treasurer, Secretary, Director
Bradley Hargreaves
56 2017 Vice President - Technology and Operations, Director
John Sanderson
66 2015 Chief Medical Officer
George Adams
2018 Director» Insider Trading
BIOGRAPHIES
Name Description
Frank McEnulty
Mr. Frank Edward McEnulty is President, Director of the Company. Mr. McEnulty also served as our Chief Financial Officer, Treasurer and Secretary. Mr. McEnulty is an experienced executive with an extensive background in finance and accounting. Since 1996, Mr. McEnulty has been the President and CEO of Meghan Matthews, Inc., a private investment company. Since 2004, Mr. McEnulty has also been a member of the board and compensation committee for Ojai Oil Company. Ojai Oil Company, currently trades on the OTC Pink marketplace. Since September 2014 until January 2015 Mr. McEnulty has been the director of Madison Technologies, Inc. From 1989 through 1995, Mr. McEnulty was the Chief Operating Officer and Vice President of Finance for Tri-Five Property Management, a foreign owned real estate investment company. Mr. McEnulty received a Masters of Business Administration from the University of Southern California and a Bachelor of Science from California State University, Long Beach.
Yanika Silina
Ms. Yanika S. Silina serves as Chief Financial Officer, Treasurer, Secretary, Director of the Company. She has worked in the accounting field for the past nine years. Since July 2008, Ms. Silina has been an accountant with Da Costa Management Corp. a management and consulting company that provides bookkeeping, accounting and regulatory compliance services to both publicly traded and private companies. Ms. Silina received her Diploma in Accounting in 2011 and currently is working towards her CMA / CPA designation. Since December 2014, Ms. Silina acts as a member of the board of directors of Kesselrun Resources Ltd. a mineral exploration company listed on the TSX Venture Exchange; from November 2013 to January 2014, Ms. Silina was Chief Financial Officer of Enfield Exploration Corp., a mineral exploration company listed on the Canadian Securities Exchange.
Bradley Hargreaves
Mr. Bradley S. Hargreaves serves as Vice President - Technology and Operations, Director of the Company. Mr. Hargreaves’ background is in engineering, with two operations journeyman tickets and four year operations certification from Shell Canada. During the past eight years Mr. Hargreaves has researched the e-balance Technology and designed and improved treatment protocols for the treatment of disabilities and related ailments. Mr. Hargreaves will provide his expertise and technical support to our research and development team and will oversee the continuous development of the project from an engineering prospective. Mr. Hargreaves has been the director of operations and principal of XC Velle Institute Inc., a privately held technology and spa company, since 2009. From approximately 2002 to 2009, Mr. Hargreaves worked operations for a privately held spa company that at one point employed up to 15 employees.
John Sanderson
Dr. John Sanderson, M.D. is Chief Medical Officer of the company since 2015. He is a stem cell researcher who began his career in clinical medicine specializing in diabetes and intravenous nutrition of critically ill patients. He has received NIH funding, has multiple issued patents and published numerous academic papers as principal investigator. While a medical director and consultant at Johnson & Johnson, Dr. Sanderson was tasked with due diligence oversight for mergers and acquisition, formulating strategic initiatives, and evaluating new technologies. In 2009 Dr. Sanderson founded Cellese Regenerative Therapeutics, Inc, a private company that focuses exclusively on the application of adult stem cells to dermatologic problems and effects of ageing; Dr. Sanderson is CEO and Chief Scientis with this company. In addition, Dr. Sanderson is a director and co-founder of Locata Corporation, a privately held technology company headquartered in Canberra, Australia. From April 2005 to January 2007, Dr. Sanderson acted as Medical Director of Johnson & Johnson’s diabetes company, LifeScan. Dr. Sanderson received his masters degree in medicine from University of Manitoba in 1979, and his masters degree in Physiologic Psychology from Occidental College, Los Angeles, CA in 1974.
George Adams
Dr. George Adams is Director of the Company. Dr. Adams is currently a Director and Chief Executive Officer of VentriPoint Diagnostics Ltd. (TSXV:VPT). Dr. Adams is a scientist and a serial entrepreneur with extensive public market experience. His previous positions include CEO of Amorfix Life Sciences (TSX:AMF), Chairman of Sernova Corp (TSXV:SVA) and President and CEO of the UT Innovations Foundation. Prior to this, Dr. Adams held research and executive positions with Boston Scientific Inc, Pfizer Inc, Corvita Canada Inc., University of Ottawa and Canadian Red Cross. Dr. Adams has been instrumental in founding over 32 companies who have raised $120 million and has been a Director of 10 venture capital funds, 10 start-up companies and two Centres of Excellence. Dr. Adams was awarded a World Economic Foundation Technology Pioneer for 2007 and TBI Company of the year in 2009. Dr. Adams has 124 scientific publications and is a reviewer for major scientific journals, federal granting agencies and Centres of Excellence. Dr. Adams obtained his BASc and MASc from the University of Waterloo and his PhD in Blood and Cardiovascular Disease, from McMaster University.
BASIC COMPENSATION
Name Fiscal Year Total
Frank McEnulty
21,600
Yanika Silina
6,000
Bradley Hargreaves
76,732
John Sanderson
273,829
George Adams
--As Of 30 May 2015
OPTIONS COMPENSATION
Name Options Value
Frank McEnulty
0 0
Yanika Silina
0 0
Bradley Hargreaves
0 0
John Sanderson
0 0
George Adams
0 0
INSIDER TRADING
Name Shares Traded Price
Jeffs (Richard Norman)
6,064 $0.31
Jeffs (Richard Norman)
2,500 $0.32
Jeffs (Richard Norman)
16,000 $0.15
Jeffs (Richard Norman)
14,700 $0.15
Jeffs (Richard Norman)
200 $0.16
Jeffs (Richard Norman)
8,500 $0.18
Jeffs (Richard Norman)
1,100 $0.17
Jeffs (Richard Norman)
50,000 $0.14
Jeffs (Richard Norman)
250 $0.12
Mcenulty (Frank)
481,016 $0.25» Full list on Insider Trading
Its time to revisit this stock.
Cmxc borads have been quiet. M pretty sure they wont be for much longer. FDA approval for professional medical use will be sooner than later and prominent blogs like Science 2.0 have picked it up. The follwing passage is a quote from their July 20th publication.
looks good. perhaps i should of grabbed some. I forgot about it. I look at so many stocks i just forget what i look at sometimes.
Hey, Shell was looking around, and found CMXC, went to I HUB , and there u were.....Here....Found this on this site.... thought u like it....Have a good weekend......
I really like this one.....
http://emerginggrowth.com/cell-medx-corp-otcqb-cmxc-climbs-31-23-moving-manufacturing-british-columbia-canada/
March 28, 2017 Cell MedX Corp. Announces FDA Registration and Update on Clinical Observational Study
https://finance.yahoo.com/news/cell-medx-corp-announces-fda-122500082.html
Just got a promo email on this ticker
HOLY CRAPOLA!!!.....Awesome news on $CMXC .......et z
Interesting a stock that went public on bio feedback? There are metaphysical stores that have these where I live. I had it done a couple times I believe.
This one is going to fly with some awareness
CMXC looking good
bids lined up at .27, just a matter of time here
$CMXC
starting to get some bid support here, just need to tighten up the spread a bit more
$CMXC
Cell MedX Corp. Receives Approval from Health Canada to Commence its Observational Clinical Trial in Canada
http://cellmedx.com/cell-medx-corp-receives-approval-health-canada-commence-observational-clinical-trial-canada/
CARSON CITY, NV / ACCESSWIRE / January 23, 2017 / Cell MedX Corp. (CMXC), Cell MedX Corp. (“Cell MedX” or the “Company”), is happy to announce that it has received an approval from Health Canada to commence its observational clinical trial in Canada.
As previously announced in the Company’s news releases dated March 22, 2016 and July 13, 2016, Cell MedX has engaged Nutrasource Diagnostics Inc. (“NDI”) to launch the observational clinical trial of its innovative and proprietary technology branded under the trade name eBalance (the “Trial”). The intent of the Trial is to assess the impact of eBalance therapy as an adjunct treatment on HbA1c after three months of therapy in relation to the subject’s baseline data and medical history. Additional objectives of the Trial will be to assess the effect of eBalance therapy on insulin resistance and sensitivity as well as on various complications caused by diabetes, such as;
Diabetic neuropathy
Diabetic foot pain and numbness
Wound healing
Blood pressure
Kidney function
The Trial will be carried out in a research facility in Hamilton, Ontario, and will adhere to an investigational protocol outlined by Cell MedX and approved by Health Canada.
The commencement of the study is pending the approval of the Ethics Board which the Company expects to receive in the first week of February.
Mr. McEnulty, the Company’s CEO, stated: “I am very excited to receive the approval from Health Canada in that it allows us to further advance research of our eBalance technology as well as its effects on both diabetes and diabetic complications.”
About Cell MedX Corp.
Cell MedX Corp. is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, high blood pressure. For more information about the Company and its technology please visit our website at: www.cellmedx.com, for the Company’s newsletter, please go to www.cellmedx.com/media/newsletters/
On behalf of the Board of Directors of Cell MedX Corp.
Frank McEnulty
Chief Executive Officer and President.
Forward Looking Statements
The information included in this press release has not been reviewed by the FDA, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company’s eBalance technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
We need to acquire additional financing or our business will fail.
We must obtain additional capital or our business will fail. In order to continue development of our eBalance Technology and to successfully complete clinical trials, we must secure more funds. Currently, we have very limited resources and have already accumulated a net loss. Financing may be subject to numerous factors including investor sentiment, acceptance of our technology and so on. We currently have no arrangements for additional financing. We may also have to borrow large sums of money that require substantial capital and interest payments.
Risks related to our stock
We expect to raise additional capital through the offering of more shares, which will result in dilution to our current shareholders.
Raising additional capital through future offerings of common stock is expected to be necessary for our Company to continue. However there is no guarantee that we will be successful in raising additional capital. Issuance of additional stock will increase the total number of shares issued and outstanding resulting in decrease of the percentage interest held by each of our shareholders.
There is a limited market for our common stock meaning that our shareholders may not be able to resell their shares.
Our common stock currently has a limited market which may restrict shareholders’ ability to resell their stock or use their stock as collateral. Thus, the shareholders may have to sell their shares privately which may prove very difficult. Private sales are more difficult and often give lower than anticipated prices.
Should a larger public market develop for our stock, future sales of shares may negatively affect their market price.
Even if a larger market develops, the shares may be sparsely traded and have wide share price fluctuations. Liquidity may be low despite there being a market, making it difficult to get a return on the investment. The price also depends on potential investor’s feelings regarding the results of our operations, the competition of other companies’ shares, our ability to generate future revenues, and market perception about future of microcurrent technologies.
Because our stock is a penny stock, stockholders will be more limited in their ability to sell their stock.
Recent Corporate Developments
The following corporate developments occurred during the quarter ended November 30, 2016, and up to the date of the filing of this report:
Letter Agreement with Jean Arnett and Brad Hargreaves
On September 26, 2016, we entered into a letter agreement (the “Letter Agreement”) with Jean Arnett and Brad Hargreaves to, among other things, cancel the unvested portion of the options granted to Ms. Arnett and Mr. Hargreaves pursuant to those separate Option Agreements between us and Ms. Arnett, and Mr. Hargreaves, each dated for reference November 25, 2014 (the “Cancelled Options”). The Cancelled Options had previously entitled Ms. Arnett and Mr. Hargreaves to collectively acquire up to 17,500,000 common shares of the Company (8,750,000 shares, each) at an initial price of $0.05 per share.
In addition, we renegotiated our consulting arrangements with Ms. Arnett and Mr. Hargreaves. Based on the Letter Agreement, we agreed to pay each of Ms. Arnett and Mr. Hargreaves CAD$5,000 per month, beginning effective August 1, 2016, for a duration of six (6) months.
Appointment of Director
On September 26, 2016, the board of directors of the Company unanimously resolved to fix the number of directors at three, and appointed Yanika Silina, our current Chief Financial Officer, as a director to fill the vacancy created by the increase in the number of directors. We did not enter into any new compensation arrangements with Ms. Silina in connection with her appointment as a director of the Company.
Private Placement Offering
On October 12, 2016, we closed a non-brokered private placement offering (the “Offering”) at a price of $0.15 per unit, by issuing 2,383,333 units for cash proceeds of $357,500 and 6,711,272 units to the holders of our notes payable for debt settlement of $1,006,691. Each unit sold under the Offering consisted of one common share of the Company and one share purchase warrant entitling the holder to purchase one additional common share for a period of five years after closing at an exercise price of $0.50 per share if exercised during the first year, $0.75 per share if exercised during the second year, $1.00 per share if exercised during the third year, $1.25 per share if exercised during the fourth year, and at $1.50 per share if exercised during the fifth year.
Loan Agreements
During the quarter ended November 30, 2016, we did not enter into any loan agreements, subsequent to November 30, 2016, we entered into loan agreements for a total of CAD$55,000, of which CAD$15,000 were loaned to us by Mr. Richard Jeffs, our major shareholder. The loans bear interest at 6% per annum, compounded monthly, are unsecured and payable on demand.
On September 30, 2016, Mr. Jeffs notified us that he had assigned all rights to his claims against the Company in the amount of $250,000 to two unaffiliated parties (the “Assignees”). The full amount of debt assigned to the Assignees was converted into the units of the Company’s common stock as part of the Offering.
$.001 per share, outstanding as of January 17, 2017 was 40,244,605.
Cell MedX Corp. Receives Data from Observational Trials in Manilla, Philippines
CARSON CITY, NV / ACCESSWIRE / January 10, 2017 / Cell MedX Corp. (CMXC), Cell MedX Corp. (“Cell MedX” or the “Company”), announces that it has received more positive observational results from our distributor, Mr. Greg Pek, in Manilla, Philippines.
Mr. Greg Pek has been conducting observational trials with the supervision of Dr. Caballeros over the past five months and has recently added Mr. Cesar Diones, a Physiotherapist, to assist in expanding the trials. There are currently twenty seven individuals participating in these trials and nearly all have expressed great improvements since commencing the observations. These individuals have expressed relief from a variety of different issues including but not limited to edema, neuropathy, kidney problems and chronic pain conditions.
Since beginning these trials, Mr. Pek has noticed that through regular sessions, usually 15 minutes, two to three times a week, these individuals continually report improvements in overall health and wellness. A 69 year old male with diabetes, arthritis and overall general pain stated: “All the pain was gone in the first week, cramps are gone and I feel stronger!” also a 61 year old female with arthritis, back pain and insomnia said “I have no more pain, I sleep well and the feeling in my hands have been restored.”
Many of these testimonials can be viewed on the Cell MedX website by clicking on the treatments tab.
Mr. McEnulty, the Company’s CEO, stated: “I am very excited by the findings of Mr. Pek’s work and we look forward to his collaborative effort with Dr. Caballeros and Mr. Diones in Manilla.”
About Cell MedX Corp.
Cell MedX Corp. is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, high blood pressure. For more information about the Company and its technology please visit our website at: www.cellmedx.com, for the Company’s weekly newsletter, please go to www.cellmedx.com/media/newsletters/
On behalf of the Board of Directors of Cell MedX Corp.
Frank McEnulty
Chief Executive Officer and President.
Forward Looking Statements
The information included in this press release has not been reviewed by the FDA, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company’s eBalance technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
Cell MedX Corp. Receives First Commercial eBalance Pro Wellness Devices
Carson City, Nevada, January 9, 2017, Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. (“Cell MedX” or the “Company”), is pleased to announce that it has received its first eBalance Pro wellness devices ready for commercial distribution. These wellness devices are designed to promote general wellness and alleviate pain caused by chronic conditions such as: sciatica, neuropathy and arthritic pain.
The eBalance Pro wellness device is an all-in-one, portable and fully automated microcurrent delivery system. This cutting-edge device’s software uses biofeedback algorithms to identify specific and personalized microcurrent frequencies to alleviate what are, in many cases, painful conditions. This device is based on the Company’s original eBalance Pro which continues to receive positive feedback. These observations are currently being conducted in Asia, Europe and North America.
Mr. McEnulty, the Company’s CEO, stated: “We are very excited to receive the new model eBalance Pro wellness devices. Our excitement is based on our belief that our eBalance technology has effected positive change in the overall wellbeing of those currently engaged in observations.”
About Cell MedX Corp.
Cell MedX Corp. is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, high blood pressure. For more information about the Company and its technology please visit our website at: www.cellmedx.com, for the Company’s weekly newsletter, please go to www.cellmedx.com/media/newsletters/
Cell MedX (CMXC) Widens Scope for Breakthrough Technology
By RYAN ALLWAY December 13th, 2016
Source: SECFilings.com
Cell MedX Corp. (OTCQB: CMXC), a development-stage biotech company focused on harnessing the power of microcurrent technologies to address numerous health conditions, recently expanded the potential addressable market for its eBalance Pro from diabetes to Parkinson’s disease, high blood pressure, and other health conditions. The move comes after early stage observations, and testimonials from volunteer subjects, revealed a much wider potential for the technology beyond their original sole focus on diabetes treatment.
In this article, we will look at the company’s decision to broaden the market scope for its eBalance technology, as well as some near-term catalysts that could boost the stock.
Broadening the Focus
Cell MedX Corp.’s discovery phase trial in February 2015 found that its eBalance Technology improved insulin sensitivity and upregulated glycolytic processes resulting in enhanced transport as well as utilization of glucose during a single treatment. With the diabetes devices market expected to reach $35.5 billion by 2024, according to Grand View Research, an approved product that increases insulin sensitivity could quickly become a blockbuster therapeutic device.
Since then, further investigations led the company to broaden its focus to include conditions like Parkinson’s disease and high blood pressure, where the company believes microcurrent technology could prove efficacious. GBI Research believes that Parkinson’s disease could be a $3.2 billion market by 2021, while Technavio expects hypertension drugs to generate more than $32 billion in sales by 2020. These are significant additional end markets for the company’s breakthrough technology.
The company’s short-term goal is to obtain approval for the eBalance technology to treat pain and address general wellness. The company aims to initially deploy pain management solutions utilizing qualified supervisory protocols, with advanced therapies for related conditions to be offered by clinicians. The team would then apply to market and distribute the device to treat a variety of other conditions – including diabetes and Parkinson’s disease – on an individualized basis, employing appropriate supervisory protocols, while potentially partnering with research institutions to further develop areas of investigation into a number of conditions where the technology has shown potential for future use.
Innovative Technology
Cell MedX Corp.’s eBalance Pro is based on a fully software-driven microcurrent technology. Using cutting-edge software, the device identifies specific frequencies for microcurrent application through the use of a bio-feedback algorithm that identifies and delivers personalized frequencies to provide optimal outcomes which address specific, and in most instances, painful conditions.
Upon the successful completion of the upcoming clinical trials, the eBalance Pro would be the only microcurrent therapy developed to treat specific medical conditions on an individualized basis. The software-driven nature of the device would also enable results to be achieved more quickly than the lengthy time required by currently available microcurrent devices typically marketed for physiotherapy purposes. If successful, the eBalance Pro would hold a significant competitive advantage when marketed as medical device specifically capable of addressing a growing list of conditions.
Microcurrent technologies have been shown to have potential benefits across a range of medical conditions. Several studies have acknowledged that microcurrents appear to play a significant role in the healing process and can promote healing in a variety of bone and skin lesions, while other studies have shown that microcurrents can have a significant impact on reducing lower back pain and other conditions.
To read full article - http://cellmedx.com/cell-medx-cmxc-widens-scope-breakthrough-technology/
Cell MedX (CMXC) Advances the Power of Microcurrents
Microcurrent therapy uses extremely low-level electrical currents that promote general wellness and alleviate complications associated with certain medical conditions. On a cellular level, the technology stimulates a dramatic increase in ATP (adenosine triphosphate) production and protein synthesis that accelerates healing and increases blood flow. This translates into decreased inflammation, reduced pain, and other beneficial effects for those suffering from a number of potentially serious health conditions.
This approach is a natural alternative to conventional therapies such as pharmaceuticals and surgical interventions. For example, using microcurrent therapies to reduce pain has the potential to reduce the excessive usage of opioid medications, as well as treat conditions for which there are no conventional therapies – such as fibromyalgia or diabetes – where existing standard-of-care options only slightly reduce complications.
In this article, we will look at how Cell MedX Corp. (CMXC) has improved upon microcurrent technology with eBalance Pro and its progress towards commercialization.
A Better Approach
The most common microcurrent therapy is known as a pulsed electrical magnetic field – or PEMF, which is applied to the skin to elicit a cellular response depending on the amplitude, frequency, and waveform. Since the late-1970s, the FDA has approved these kinds of devices to treat everything from non-union fractures to major depressive disorders, although their effectiveness in treating these conditions is widely documented, results tend to vary.
Cell MedX Corp. (CMXC) is pioneering a new microcurrent therapy device called eBalance that uses proprietary software to read the body’s response to the microcurrents being applied, and uses this information to fine-tune a range of electrical frequencies designed to target specific conditions. The company believes that its technology has the potential to address the complications associated with a growing list of medical conditions.
This list of conditions represents multi-billion dollar markets, of which a large percentage of the United States’ population suffers from daily, with few alternative treatment options.
Observational Studies & Clinical Trial
Cell MedX Corp. (CMXC) is initially focusing its clinical protocols on safely studying the effects of its eBalance Pro device on diabetes and related complications. The observations and testimonials resulting from the company’s early observations are currently being reported on Cell MedX’s website on an ongoing basis, but investors will have to wait for the results from its initial observational clinical trials to determine the efficacy profile anticipated for the technology.
Cell MedX plans to begin observational clinical trials early next year with the goal of obtaining Health Canada approval to use eBalance Pro as a medical device for the treatment of diabetes and related complications. While the company is moving to obtain approval from Health Canada, similar activities are under way in Europe and Asia, and as data becomes available management believes it will be able to more readily develop an FDA approval pathway for the U.S. marketplace.
Looking Ahead
Investors interested in the exploding wellness industry may want to take a closer look at Cell MedX Corp. (OTCQB: CMXC) given its unique approach to microcurrent therapies and its potential to address several multi-billion dollar market opportunities. With Canadian observational clinical trials set to begin shortly, the company is building a growing pipeline of catalysts that could drive value for shareholders over the long-term.
For more information, visit the company’s website at http://cellmedx.com/
Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. In particular, Cell MedX Corp. has not yet begun its clinical trials, which are pending Health Canada approval. There is no assurance that the results of Cell MedX Corp.’s clinical observational trials will be successful, or that it will be able to obtain licensing or approval from Health Canada, the FDA or any other regulatory agencies.
Cell MedX Corp. Appoints Gregory Pek to the Advisory Board and as a Distributor
LAS VEGAS, NV--(Marketwired - Nov 21, 2016) - Cell MedX Corp. (OTCQB: CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), a development stage bio-tech company focused on the commercialization and development of microcurrent therapeutic devices that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson's disease, high blood pressure, is pleased to announce that it has appointed Gregory Pek to the Company's advisory board and as a distributor for Hong Kong and the Philippines.
Gregory Pek is a Canadian who has lived in Asia for some 22 years. Mr. Pek's career began in accounting, which led to him becoming an entrepreneur more than 30 years ago. Mr. Pek has been the founder and CEO of various public companies either listed on the U.S. or Canadian markets as well as a Deputy Managing Director of two companies listed in Hong Kong. Along with his extensive experience with early stage development companies, Mr. Pek, has a wide range of experience in distribution, logistics and financial services.
Mr. Pek, under the supervision of a physician, commenced his own observational trials of the eBalance device in Manila, Philippines. Due to the positive response and testimonials of over 25 subjects, Mr. Pek has been devoting the majority of his time to this project.
Mr. Pek will assist the Company in a wide range of functions including, but not limited to; input into the structure of the observational clinical studies and developing marketing strategies in Asia, overall business strategy, and financing.
Mr. Pek commented that, "It is incredibly exciting to be a part of Cell MedX's project, and witness its technology along with hearing the beneficial results attested to by those involved in the observational studies."
Mr. McEnulty, the Company's CEO, stated, "We are excited to welcome Greg Pek to our advisory board. He is a proven entrepreneur with a detailed understanding of business in Asia. Mr. Pek has, very quickly, established himself as a major source of invaluable information for our current project and further development of our eBalance technology."
About Cell MedX Corp.
Cell MedX Corp. is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson's disease, high blood pressure. For more information about the Company and its technology please visit our website at: www.cellmedx.com, for the Company's weekly newsletter, please go to www.cellmedx.com/media/newsletters/
Cell MedX Corp. (CMXC) Engages Tamarack Advisors
DENVER, CO / ACCESSWIRE / November 3, 2016 / Cell MedX Corp. (CMXC), Cell MedX Corp. ("Cell MedX" or the "Company"), a development stage company focused on the commercialization of therapeutic devices for patients living with diseases such as diabetes, today announced that it has engaged Tamarack Advisors Inc. to develop an investor communication and outreach program. With a network of hundreds of thousands of sophisticated financial professionals, Tamarack Advisors is a leader in helping emerging public companies reach targeted investor audiences.
Cell MedX Corp. is developing cutting-edge frequency specific microcurrent technologies designed to help treat chronic and acute conditions for both clinical and self-management care. Over the past several years, the Company has been working on the development of an innovative microcurrent technology called eBalance that emits electrical frequencies that are best suited to specific conditions, such as diabetes or pain management.
The underlying technology uses the principles of microcurrents to effectuate positive outcomes for individuals suffering from a wide range of conditions. In a number of clinical studies, the topical application of microcurrents has increased production of adenosine triphosphate ("ATP") - the energy stored by cells - by up to 500%. This increased cellular function is theorized to reinvigorate cells and potentially reverse damage from illness.
The Company's eBalance technology is set to undergo observational clinical trials to evaluate its safety and efficacy. Early users of the prototype devices have reported a range of positive benefits that the Company has made available on its website (www.cellmedx.com/observations). With initial funding in place to acquire devices for the trial, investors could see tangible data early next year.
The Company believes that the market for eBalance technology could be significant since it improves upon traditional microcurrent technologies by customizing frequencies. Wellness devices - like TENS units used for pain management – have sold millions of units around the world. Meanwhile, approved medical devices that have undergone clinical trials can sell for much higher price points given the potential for reimbursements from insurance companies.
Investors interested in the medical device space may want to keep an eye on Cell MedX Corp. (CMXC) as it progresses through observational clinical trials to secure approval for its eBalance technology. In particular, investors in companies like Zynex Inc. (OTCQB:ZYXI) or larger medical devices companies like Medtronic plc (NASDAQ:MDT) may want to take a closer look.
About Cell MedX Corp.
Cell MedX Corp. is an early development stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage both the illness and related complications. For more information about the Company and its technology please visit our website at: http://cellmedx.com/, for the Company's weekly newsletter, please go to http://cellmedx.com/media/newsletters/.
For further information visit: http://cellmedx.com/
Or phone: 1-844-238-2692
About Tamarack Advisors Inc.
Tamarack Advisors Inc. is a leading provider of investor communication and outreach services for emerging public companies. With an extensive network of investors and in-depth marketing expertise, the company helps clients reach and cultivate a network of long-term investors and establish a reliable shareholder base.
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
138
|
Created
|
11/19/14
|
Type
|
Free
|
Moderators |
Electroceuticals: Microcurrents as medicine
Bioelectric medicine was born 60 years ago with the pacemaker. Using electro-technologies to modify bodily functions grew slowly and steadily after that … from pacemakers in 1958, to spinal cord stimulation (SCS) in 1967, to inner ear implants in 1978… bioelectric medicine has come a long way towards extending the lives of patients.
Discoveries like those were so sporadic and treated so many different symptoms that most people didn’t realize they were connected… yet they’re all bioelectronics, also called electro-medicine.
With advances in micro processing this field is suddenly exploding, and yesterday’s slow-and-seldom breakthroughs have turned into a tsunami of rapid discoveries and new treatments. These new treatments are so much more flexible and powerful that they’ve caught the attention of a number of major corporations who are developing electroceutical devices of their own.
This Technology Just Spawned a New Medical Sector with a Fast Growing $35 Billion Market
Grandview Research predicts that electroceutical/bioelectric medicine will be a $35.5 billion market by 2025. Many forward-thinking investors have already taken positions in bioelectric medicine, as the field is still young and has enormous growth potential. Another sign that bioelectric medicine is on firm footing is the number of major corporations that are entering the sector, below are examples of 4 corporations making strides in bioelectric medicine.
GlaxoSmithKline (GSK), with support from Alphabet, set up Galvani Bioelectronics to work on an implant device that will wrap around a bundle of nerves to treat diseases.
Boston Scientific (BSX) & Medtronic (MDX) – Both companies have a long history in bioelectronics with pacemakers and spinal cord stimulation devices.
Nevro Corp. (NVRO) – Makes pain control devices using spinal cord stimulation (SCS).
The common theme with the above examples is that their procedures are all invasive in nature. Standing out amongst these large corporations is a small company by the name of Cell MedX who has just completed observational clinical trials for their eBalance device.
Cell MedX Corp. (CMXC) – Is a pure-play electroceutical that has just completed observational clinical trials for its eBalance device.
Unique Opportunity in a Pure Electroceuticals Play
The very nature of Cell MedX’s eBalance device is very different from other microcurrent systems. Instead of stimulating the spinal cord or muscles or providing other localized application of electrical stimulation, eBalance instead delivers microcurrents in various strengths, frequencies and waveforms through the body in 15 to 30 minute treatments.
Observational Clinical Trial Results as Reported by the Company
An observational clinical trial was completed on diabetic subjects using 3 months of eBalance treatments twice weekly (the “Trial”) with no significant side effects or safety issues. The following results were observed during the Trial;
Diabetes
After three months of bi-weekly eBalance treatments, the average fasting blood glucose levels declined by 12.3% and plasma insulin declined by 46.7%. These results indicate that, on average, the blood glucose uptake was increased and that less insulin was required to achieve that uptake. A longer double-blind, placebo controlled study may be conducted in the future to determine if grater effects are achieved as seen in individuals who have used the device over extended periods of time.
Blood pressure
After 7 weeks of treatments, systolic pressure, the higher amount of pressure in the arteries during the contraction of the heart muscle, declined by 9.6% and diastolic pressure, the lower pressure number in the arteries when the heart muscle is between beats, declined by 10.4%. The Company is planning to undertake further studies on subjects with higher blood pressures to determine if a proportional effect is obtained as has been observed with in individuals who have used the eBalanceTM device. A 10% decrease in blood pressure for individuals at risk from high blood pressure could be very beneficial without the side effects of medications.
Pain and numbness
Neuropathy is nerve damage that can occur with diabetes as a result of high blood glucose levels and high blood pressure. The damage most often affects the extremities and causes pain, tingling or numbness in the hands, arms, legs and feet. Only two subjects suffered from pain at the beginning of the Trial and both reported feeling either less pain or reduced coldness or numbness in their extremities. These findings support our individual findings and he Company is wanting to conduct further studies on neuropathy and other forms of chronic pain, such as gout, migraines and inflammation.
Kidney function
Nephropathy is damage caused to the small blood vessels in the kidneys by high blood glucose levels and high blood pressure that prevents them from functioning properly or even causes them to fail completely. When the blood vessels in the kidneys are injured, the kidneys cannot clean the blood properly. The body will retain more water and salt than it should, which can result in weight gain and edema. In the Trial, there were some indications that eBalance treatments improved kidney function which is supported by individual observations of significant reductions of edema. A longer study on studies on kidney function is highly desirable.
Cell MedX Corp. (CMXC), a fully-reporting US-listed company and a reporting issuer in Canada
Investing in Cell MedX (CMXC)
Unique Electroceutical Opportunity—CellMedX offers a pure play on the fast-evolving field of electroceuticals.
Millions of Potential Users—Having completed observational trials to demonstrate the efficacy for diabetes, blood sugar and blood pressure treatment, CellMedX is targeting the
global population of 380 million diabetics and 1.1 Billion people suffering from high blood pressure.
Meaningful Innovation—The eBalance device may prove to be an important breakthrough in diabetes management.
Outstanding safety—Even insulin therapy can be dangerous for diabetics, but the eBalance microcurrent treatments through its observational clinical trials has demonstrated no harmful side effects.
Easy to use— eBalance incorporates a user-friendly interface.
Pipeline Potential —Outstanding potential for follow-on devices built with the same technology to address other health problems.
Global Ambition— Cell MedX (CMXC) is taking the necessary steps to gain approval in the US, EU, and Commonwealth countries.
https://www.grandviewresearch.com/press-release/global-electroceuticals-bioelectric-medicine-market
Continue reading about the eBalance Solution
Forward Looking Statements
The information included in this press release has not been reviewed by the FDA, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company’s eBalance technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
As we begin this new millennium, we rely on various forms of technology to diagnose our patients through an ever increasing list of new diseases. New therapeutic technologies for a variety of disorders also offer a remarkable and unprecedented track record both in safety and efficacy.
The application of electromagnetic forces to human tissues to effect change has been around since the 19th century. A good deal of that was wishful thinking or deliberate deception. But what has survived, and is now seeing resurgence in legitimate, peer-reviewed biologic research, is the concept of molecular bioelectricity and its role in cell-to-cell signaling. Ion flows and trans-membrane gradients produced by ion channels and pumps are key regulators of cell proliferation, migration, and differentiation. Now, instructive roles for bioelectrical gradients in embryogenesis, regeneration, and neoplasm are being revealed. There is speculation of “cracking the bioelectric code” with the same excitement that portended the cracking of the genetic code.
Also helpful in the discovery pathway is the fact that diabetics have been benefiting from micro-current delivery devices since 1987. Treatment of diabetic neuropathy using programmed delivery of electrical currents is well known, as is the use of microcurrents for non-healing wounds. The e-balance Technology is different. Based on first-in-human observations carefully documented by the discoverers of this technology, a specific device with a specific set of bioelectric signals of known waveform, frequency, amplitude, pulse, and duration, accompanied by sensing circuits that respond to fluctuations in the body’s response, in a closed feedback loop, effect global improvements in Type 1 diabetes.
Conventional medical treatments do not take advantage of the potent ways that energy can transmit information in biological systems. Healthy and unhealthy tissues have distinct electromagnetic properties that can be detected in scanned images. Lipton observes that “diseased tissue emits its own unique energy signature emitted by surrounding healthy cells”. He goes on to suggest that there is enough scientific evidence to tailor energy and waveforms that act as therapeutic agents in much the same way that we now modulate chemical structures with drugs.
Cell MedX products employ energy in nature and are designed to provide an enhanced treatment result to conventional therapies in the management of pain and chronic disease conditions. The high-tech advancements of the 21st century can now provide a new quality of life and lifestyle.
Our products are a breakthrough approach to support a new age of predictive, personalized wellness treatments grounded in each person’s personal profile. The power of direct-to-consumer wellness with the potential to manage diseases/issues we have inherited, and what can be forestalled by specific lifestyle treatments is the 21st century model.
Carson City, Nevada, June 28, 2019, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, is pleased to announce that on June 24, 2019, the Company closed the first tranche of its non-brokered private placement … Continued
Carson City, Nevada, June 21, 2019, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that it has retained Think Ink Marketing Data & Email Services, Inc. (“Think Ink”) to develop an investor … Continued
Carson City, Nevada, May 30, 2019, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, has arranged a non-brokered private placement offering (the “Offering”) set at a price of $0.12 per Unit for up to … Continued
Carson City, Nevada, March 27, 2019, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that on March 21, 2019, the Company entered into a definitive agreement for exclusive worldwide distribution rights of … Continued
Carson City, Nevada, February 12, 2019, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), an early development stage biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness is pleased to announce significant progress toward obtaining premarket clearance in the US for its eBalance device. … Continued
Carson City, Nevada, December 31, 2018, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announces that on December 27, 2018, the Company entered into an Agreement with Mr. Richard Jeffs (the … Continued
Carson City, Nevada, December 12, 2018, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN) (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness is pleased to announce that it has successfully completed its first 100 Canadian manufactured eBalance devices. Upon … Continued
Carson City, Nevada, December 4, 2018, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN), (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that the Company received electrical and safety certification for the Company’s eBalance Pro device (the … Continued
Carson City, Nevada, September 14, 2018, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN), (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that on September 10, 2018, the Company entered into a non-binding letter of intent (the “LOI”) with … Continued
Carson City, Nevada, May 7, 2018, Cell MedX Corp. (OTCQB: CMXC, 9CX:MUN), (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that, effective April 30, 2018, Dr. Terrance Owen resigned from his management and directorship
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |